Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01011738




Registration number
NCT01011738
Ethics application status
Date submitted
10/11/2009
Date registered
11/11/2009
Date last updated
10/04/2017

Titles & IDs
Public title
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
Scientific title
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)
Secondary ID [1] 0 0
MV22009
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis B, Chronic 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Cohort -

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Hepatitis B Virus Surface Antigen Clearance
Timepoint [1] 0 0
Up to 276 Weeks
Primary outcome [2] 0 0
Predictive Values of Early on Treatment Response for Hepatitis B Surface Antigen Clearance 3 Years Post-Treatment- Hepatitis B Virus e Antigen Positive Participants
Timepoint [2] 0 0
Up to 276 Weeks
Primary outcome [3] 0 0
Predictive Values of Early on Treatment Response for Hepatitis B Surface Antigen Clearance 3 Years Post-Treatment- Hepatitis B Virus e Antigen Negative Participants
Timepoint [3] 0 0
Up to 276 Weeks
Secondary outcome [1] 0 0
Percentage of Participants With Suppression of Hepatitis B Virus Deoxyribonucleic Acid to <2,000 International Units Per Milliliter
Timepoint [1] 0 0
Up to 276 Weeks
Secondary outcome [2] 0 0
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion in Hepatitis B Virus e Antigen Positive Participants
Timepoint [2] 0 0
Up to 276 Weeks
Secondary outcome [3] 0 0
Percentage of Participants With Hepatitis B Virus e Antigen Loss in Hepatitis B Virus e Antigen Positive Participants
Timepoint [3] 0 0
Up to 276 Weeks
Secondary outcome [4] 0 0
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion and Hepatitis B Virus Deoxyribonucleic Acid <2000IU/mL in Hepatitis B Virus e Antigen Positive Participants
Timepoint [4] 0 0
Up to 276 Weeks
Secondary outcome [5] 0 0
Percentage of Participants With Hepatitis B Surface Antigen Seroconversion
Timepoint [5] 0 0
Up to 276 Weeks
Secondary outcome [6] 0 0
Quantitative Hepatitis B Surface Antigen
Timepoint [6] 0 0
Up to 276 Weeks
Secondary outcome [7] 0 0
Percentage of Participants With Normalization of Alanine Transaminase
Timepoint [7] 0 0
Up to 276 Weeks
Secondary outcome [8] 0 0
Alanine Transaminase Ratio Over Time by Hepatitis B Virus e Antigen Status
Timepoint [8] 0 0
Up to 276 Weeks
Secondary outcome [9] 0 0
Number of Participants With Chronic Hepatitis B - Associated Clinical Endpoints- Liver Transplantation, Hepatocellular Carcinoma, and Liver Decompensation
Timepoint [9] 0 0
Up to 276 Weeks
Secondary outcome [10] 0 0
Number of Participants With Chronic Hepatitis B Associated Clinical Endpoints- Liver Cirrhosis
Timepoint [10] 0 0
Up to 276 Weeks
Secondary outcome [11] 0 0
Number of Participants With Serious Adverse Drug Reactions
Timepoint [11] 0 0
Up to 276 Weeks
Secondary outcome [12] 0 0
Number of Participants With Non-Serious Adverse Drug Reactions
Timepoint [12] 0 0
Up to 276 Weeks
Secondary outcome [13] 0 0
Number of Participants With Adverse Events and Serious Adverse Events
Timepoint [13] 0 0
Up to 276 Weeks
Secondary outcome [14] 0 0
Number of Deaths During Observation Period
Timepoint [14] 0 0
Up to 276 Weeks

Eligibility
Key inclusion criteria
* adult patient, >/= 18 years of age
* chronic hepatitis B
* treatment with peginterferon alfa-2A
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* coinfection with HAV, HCV and HIV

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/04/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/11/2014
Sample size
Target
Accrual to date
Final
1842
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Graz
Country [2] 0 0
Austria
State/province [2] 0 0
Innsbruck
Country [3] 0 0
Austria
State/province [3] 0 0
Linz
Country [4] 0 0
Austria
State/province [4] 0 0
Wien
Country [5] 0 0
Bahrain
State/province [5] 0 0
Manama
Country [6] 0 0
Bangladesh
State/province [6] 0 0
Dhaka
Country [7] 0 0
Bosnia and Herzegovina
State/province [7] 0 0
Banja Luka
Country [8] 0 0
Bosnia and Herzegovina
State/province [8] 0 0
Bihac
Country [9] 0 0
Bosnia and Herzegovina
State/province [9] 0 0
Mostar
Country [10] 0 0
Bosnia and Herzegovina
State/province [10] 0 0
Sarajevo
Country [11] 0 0
Bosnia and Herzegovina
State/province [11] 0 0
Tuzla
Country [12] 0 0
Bosnia and Herzegovina
State/province [12] 0 0
Zenica
Country [13] 0 0
Bulgaria
State/province [13] 0 0
Sofia
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Varna
Country [15] 0 0
China
State/province [15] 0 0
Beijing
Country [16] 0 0
China
State/province [16] 0 0
Chengdu
Country [17] 0 0
China
State/province [17] 0 0
Chongqing
Country [18] 0 0
China
State/province [18] 0 0
Guangzhou
Country [19] 0 0
China
State/province [19] 0 0
Hangzhou
Country [20] 0 0
China
State/province [20] 0 0
Harbin
Country [21] 0 0
China
State/province [21] 0 0
Jinan
Country [22] 0 0
China
State/province [22] 0 0
Nanjing
Country [23] 0 0
China
State/province [23] 0 0
Shanghai
Country [24] 0 0
China
State/province [24] 0 0
Shen Zhen
Country [25] 0 0
China
State/province [25] 0 0
ShenYang
Country [26] 0 0
China
State/province [26] 0 0
Shi Jiazhuang
Country [27] 0 0
China
State/province [27] 0 0
Shijiazhuang
Country [28] 0 0
China
State/province [28] 0 0
Urumqi
Country [29] 0 0
China
State/province [29] 0 0
Wenzhou
Country [30] 0 0
China
State/province [30] 0 0
Xi'an
Country [31] 0 0
Egypt
State/province [31] 0 0
Cairo
Country [32] 0 0
Egypt
State/province [32] 0 0
Giza
Country [33] 0 0
Egypt
State/province [33] 0 0
Mansoura
Country [34] 0 0
France
State/province [34] 0 0
Aix En Provence
Country [35] 0 0
France
State/province [35] 0 0
Amiens
Country [36] 0 0
France
State/province [36] 0 0
Angers
Country [37] 0 0
France
State/province [37] 0 0
Argenteuil
Country [38] 0 0
France
State/province [38] 0 0
Avignon
Country [39] 0 0
France
State/province [39] 0 0
Besancon
Country [40] 0 0
France
State/province [40] 0 0
Bobigny
Country [41] 0 0
France
State/province [41] 0 0
Bondy
Country [42] 0 0
France
State/province [42] 0 0
Bordeaux
Country [43] 0 0
France
State/province [43] 0 0
Bourgoin Jallieu
Country [44] 0 0
France
State/province [44] 0 0
Caen
Country [45] 0 0
France
State/province [45] 0 0
Chambray Les Tours
Country [46] 0 0
France
State/province [46] 0 0
Clamart
Country [47] 0 0
France
State/province [47] 0 0
Clermont Ferrand
Country [48] 0 0
France
State/province [48] 0 0
Clichy
Country [49] 0 0
France
State/province [49] 0 0
Corbeil Essonnes
Country [50] 0 0
France
State/province [50] 0 0
Creil
Country [51] 0 0
France
State/province [51] 0 0
Creteil
Country [52] 0 0
France
State/province [52] 0 0
Dijon
Country [53] 0 0
France
State/province [53] 0 0
Evry
Country [54] 0 0
France
State/province [54] 0 0
Grasse
Country [55] 0 0
France
State/province [55] 0 0
La Tronche
Country [56] 0 0
France
State/province [56] 0 0
Lagny Sur Marne
Country [57] 0 0
France
State/province [57] 0 0
Le Kremlin Bicetre
Country [58] 0 0
France
State/province [58] 0 0
Le Mans
Country [59] 0 0
France
State/province [59] 0 0
Lille
Country [60] 0 0
France
State/province [60] 0 0
Limoges
Country [61] 0 0
France
State/province [61] 0 0
Lyon
Country [62] 0 0
France
State/province [62] 0 0
Marseille
Country [63] 0 0
France
State/province [63] 0 0
Metz
Country [64] 0 0
France
State/province [64] 0 0
Montauban
Country [65] 0 0
France
State/province [65] 0 0
Montivilliers
Country [66] 0 0
France
State/province [66] 0 0
Montpellier
Country [67] 0 0
France
State/province [67] 0 0
Mulhouse
Country [68] 0 0
France
State/province [68] 0 0
Nantes
Country [69] 0 0
France
State/province [69] 0 0
Nimes
Country [70] 0 0
France
State/province [70] 0 0
Niort
Country [71] 0 0
France
State/province [71] 0 0
Orleans
Country [72] 0 0
France
State/province [72] 0 0
Paris
Country [73] 0 0
France
State/province [73] 0 0
Perpignan
Country [74] 0 0
France
State/province [74] 0 0
Pessac
Country [75] 0 0
France
State/province [75] 0 0
Reims
Country [76] 0 0
France
State/province [76] 0 0
Rennes
Country [77] 0 0
France
State/province [77] 0 0
Rouen
Country [78] 0 0
France
State/province [78] 0 0
Saint Laurent Du Var
Country [79] 0 0
France
State/province [79] 0 0
St Maurice
Country [80] 0 0
France
State/province [80] 0 0
Strasbourg
Country [81] 0 0
France
State/province [81] 0 0
Toulon
Country [82] 0 0
France
State/province [82] 0 0
Toulouse
Country [83] 0 0
France
State/province [83] 0 0
Vandoeuvre-les-nancy
Country [84] 0 0
France
State/province [84] 0 0
Villejuif
Country [85] 0 0
Germany
State/province [85] 0 0
Berlin
Country [86] 0 0
Germany
State/province [86] 0 0
Bonn
Country [87] 0 0
Germany
State/province [87] 0 0
Düsseldorf
Country [88] 0 0
Germany
State/province [88] 0 0
Erlangen
Country [89] 0 0
Germany
State/province [89] 0 0
Essen
Country [90] 0 0
Germany
State/province [90] 0 0
Frankfurt am Main
Country [91] 0 0
Germany
State/province [91] 0 0
Freiburg
Country [92] 0 0
Germany
State/province [92] 0 0
Giessen
Country [93] 0 0
Germany
State/province [93] 0 0
Hamburg
Country [94] 0 0
Germany
State/province [94] 0 0
Hamm
Country [95] 0 0
Germany
State/province [95] 0 0
Hannover
Country [96] 0 0
Germany
State/province [96] 0 0
Heidelberg
Country [97] 0 0
Germany
State/province [97] 0 0
Herne
Country [98] 0 0
Germany
State/province [98] 0 0
Jena
Country [99] 0 0
Germany
State/province [99] 0 0
Kiel
Country [100] 0 0
Germany
State/province [100] 0 0
Lübeck
Country [101] 0 0
Germany
State/province [101] 0 0
Magdeburg
Country [102] 0 0
Germany
State/province [102] 0 0
Mainz
Country [103] 0 0
Germany
State/province [103] 0 0
München
Country [104] 0 0
Germany
State/province [104] 0 0
Münster
Country [105] 0 0
Germany
State/province [105] 0 0
Nürnberg
Country [106] 0 0
Germany
State/province [106] 0 0
Offenburg
Country [107] 0 0
Germany
State/province [107] 0 0
Salzgitter
Country [108] 0 0
Germany
State/province [108] 0 0
Stuttgart
Country [109] 0 0
Germany
State/province [109] 0 0
Ulm
Country [110] 0 0
Germany
State/province [110] 0 0
Wuerzburg
Country [111] 0 0
Germany
State/province [111] 0 0
Wuppertal
Country [112] 0 0
Hong Kong
State/province [112] 0 0
Tuen Mun
Country [113] 0 0
India
State/province [113] 0 0
Delhi
Country [114] 0 0
India
State/province [114] 0 0
Gurgaon
Country [115] 0 0
India
State/province [115] 0 0
Guwahati
Country [116] 0 0
India
State/province [116] 0 0
Mumbai
Country [117] 0 0
India
State/province [117] 0 0
Pune
Country [118] 0 0
India
State/province [118] 0 0
Trivandrum
Country [119] 0 0
Indonesia
State/province [119] 0 0
Bandung
Country [120] 0 0
Indonesia
State/province [120] 0 0
Jakarta
Country [121] 0 0
Indonesia
State/province [121] 0 0
Surabaya
Country [122] 0 0
Indonesia
State/province [122] 0 0
Tangerang
Country [123] 0 0
Ireland
State/province [123] 0 0
Dublin
Country [124] 0 0
Jordan
State/province [124] 0 0
Amman
Country [125] 0 0
Jordan
State/province [125] 0 0
Irbid
Country [126] 0 0
Korea, Republic of
State/province [126] 0 0
Anyang
Country [127] 0 0
Korea, Republic of
State/province [127] 0 0
Busan
Country [128] 0 0
Korea, Republic of
State/province [128] 0 0
Chooncheon
Country [129] 0 0
Korea, Republic of
State/province [129] 0 0
Daegu
Country [130] 0 0
Korea, Republic of
State/province [130] 0 0
Daejeon
Country [131] 0 0
Korea, Republic of
State/province [131] 0 0
Incheon
Country [132] 0 0
Korea, Republic of
State/province [132] 0 0
Jeollabuk-do
Country [133] 0 0
Korea, Republic of
State/province [133] 0 0
Seoul
Country [134] 0 0
Korea, Republic of
State/province [134] 0 0
Seoungnamsi
Country [135] 0 0
Korea, Republic of
State/province [135] 0 0
Ulsan
Country [136] 0 0
Lebanon
State/province [136] 0 0
Beirut
Country [137] 0 0
Macedonia, The Former Yugoslav Republic of
State/province [137] 0 0
Skopje
Country [138] 0 0
Morocco
State/province [138] 0 0
Casablanca
Country [139] 0 0
Morocco
State/province [139] 0 0
Fes
Country [140] 0 0
Morocco
State/province [140] 0 0
Rabat
Country [141] 0 0
New Zealand
State/province [141] 0 0
Auckland
Country [142] 0 0
New Zealand
State/province [142] 0 0
Hamilton
Country [143] 0 0
New Zealand
State/province [143] 0 0
Whakatane
Country [144] 0 0
Pakistan
State/province [144] 0 0
Faisalabad
Country [145] 0 0
Pakistan
State/province [145] 0 0
Islamabad
Country [146] 0 0
Pakistan
State/province [146] 0 0
Karachi
Country [147] 0 0
Pakistan
State/province [147] 0 0
Lahore
Country [148] 0 0
Pakistan
State/province [148] 0 0
Peshawar
Country [149] 0 0
Pakistan
State/province [149] 0 0
Rawalpindi
Country [150] 0 0
Poland
State/province [150] 0 0
Bialystok
Country [151] 0 0
Poland
State/province [151] 0 0
Bydgoszcz
Country [152] 0 0
Poland
State/province [152] 0 0
Chorzow
Country [153] 0 0
Poland
State/province [153] 0 0
Gdansk
Country [154] 0 0
Poland
State/province [154] 0 0
Krakow
Country [155] 0 0
Poland
State/province [155] 0 0
Lancut
Country [156] 0 0
Poland
State/province [156] 0 0
Lodz
Country [157] 0 0
Poland
State/province [157] 0 0
Warszawa
Country [158] 0 0
Poland
State/province [158] 0 0
Wroclaw
Country [159] 0 0
Poland
State/province [159] 0 0
Zielona Góra
Country [160] 0 0
Portugal
State/province [160] 0 0
Lisboa
Country [161] 0 0
Portugal
State/province [161] 0 0
Porto
Country [162] 0 0
Romania
State/province [162] 0 0
Bucharest
Country [163] 0 0
Romania
State/province [163] 0 0
Craiova
Country [164] 0 0
Saudi Arabia
State/province [164] 0 0
Alkhobar
Country [165] 0 0
Saudi Arabia
State/province [165] 0 0
Riyadh
Country [166] 0 0
Saudi Arabia
State/province [166] 0 0
Tabuk
Country [167] 0 0
Thailand
State/province [167] 0 0
Bangkok
Country [168] 0 0
Thailand
State/province [168] 0 0
Chiang Mai
Country [169] 0 0
Thailand
State/province [169] 0 0
Songkhla
Country [170] 0 0
United Arab Emirates
State/province [170] 0 0
Dubai
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Hull
Country [172] 0 0
United Kingdom
State/province [172] 0 0
London
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated. Patients included in the study will be followed for the duration of their treatment and for up to 3 years thereafter.
Trial website
https://clinicaltrials.gov/study/NCT01011738
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01011738